Valuation : Amicus Therapeutics, Inc.

Market Cap 4.55B 3.93B 3.7B 3.38B 6.3B 432B 6.35B 43.78B 16.98B 220B 17.08B 16.71B 722B P/E 2024
-51.1x
P/E 2025 -162x
Enterprise Value 4.7B 4.06B 3.82B 3.49B 6.5B 446B 6.56B 45.21B 17.54B 227B 17.64B 17.26B 746B EV / Sales 2024
5.69x
EV / Sales 2025 7.18x
Free-Float
99.31%
Yield 2024 *
-
Yield 2025 -
1 day+0.21%
6 months+0.84%
Current year+1.76%
Current year 14.2
Extreme 14.205
14.5
1 year 7.61
Extreme 7.61
14.5
3 years 5.51
Extreme 5.51
14.57
5 years 5.51
Extreme 5.51
14.57
10 years 4.41
Extreme 4.41
25.39
Date Insider Type Main position Quantity % Market Cap. Importance
27/04/26 Issuer sale

General Counsel

1,264,993 0.4029%
27/04/26 Issuer sale

Director

395,940 0.1261%
27/04/26 Issuer sale

Chairman

419,487 0.1336%
Change 5-day change 1-year change 3-year change Capi.($)
+0.21%-.--%+90.91%+12.15% 4.55B
+0.97%-1.75%+2.17%+18.46% 49.74B
-0.30%-1.02%+451.04%+496.95% 44.98B
+2.13%+1.70%+38.27%+17.61% 42.52B
+0.87%-3.88%+18.21%+73.17% 40.78B
-0.90%-1.74%+15.20%+48.44% 32.89B
+2.71%+5.66% - - 17.09B
+1.68%-3.43%+24.71%+116.83% 16.28B
+1.70%-1.75%+12.00%+28.50% 14.4B
+3.34%-1.98%+78.65%+39.19% 13.48B
Average +1.24%-2.16%+81.24%+94.59% 27.67B
Weighted average by Cap. +0.99%-2.21%+97.51%+121.31%

Financials

2024 2025
Net sales 528M 456M 429M 392M 731M 50.17B 737M 5.08B 1.97B 25.51B 1.98B 1.94B 83.82B 634M 547M 515M 470M 878M 60.22B 885M 6.1B 2.37B 30.62B 2.38B 2.33B 101B
Net income -56.11M -48.42M -45.58M -41.62M -77.66M -5.33B -78.29M -540M -209M -2.71B -211M -206M -8.9B -27.11M -23.4M -22.03M -20.11M -37.53M -2.57B -37.83M -261M -101M -1.31B -102M -99.57M -4.3B
Net Debt 194M 167M 157M 144M 268M 18.39B 270M 1.86B 723M 9.35B 727M 711M 30.73B 149M 128M 121M 110M 206M 14.13B 208M 1.43B 555M 7.19B 559M 547M 23.61B
Logo Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
Employees
511
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. FOLD Stock